Journal
VACCINE
Volume 30, Issue 29, Pages 4328-4335Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.11.011
Keywords
Allergy; Allergen; Allergy vaccination; Allergy vaccines; Hypoallergens
Categories
Funding
- Austrian Science Fund (FWF) [P 23350] Funding Source: researchfish
- Austrian Science Fund FWF [P 23350, F 1815] Funding Source: Medline
Ask authors/readers for more resources
Hundred years ago therapeutic vaccination with allergen-containing extracts has been introduced as a clinically effective, disease-modifying, allergen-specific and long-lasting form of therapy for allergy, a hypersensitivity disease affecting more than 25% of the population. Today, the structures of most of the disease-causing allergens have been elucidated and recombinant hypoallergenic allergen derivatives with reduced allergenic activity have been engineered to reduce side effects during allergen-specific immunotherapy (SIT). These recombinant hypoallergens have been characterized in vitro, in experimental animal models and in clinical trials in allergic patients. This review provides a summary of the molecular, immunological and preclinical evaluation criteria applied for this new generation of allergy vaccines. Furthermore, we summarize the mechanisms underlying SIT with recombinant hypoallergens which are thought to be responsible for their therapeutic effect. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available